Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kangmei Pharmaceutical Co Ltd (600518) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8057
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kangmei Pharmaceutical Co Ltd (Kangmei) is a manufacturer and distributor of herbal medicine. The company provides herbal raw materials and preparations. Kangmei products include Chinese herbal medicine, bottled single product, hong mei life, xinkaihe senate, chinese medicine derived, medicine, chemical drugs and ju huang tea among others. It provides chemical drugs such as clarithromycin dispersible tablets, doxazosin mesylate tablets, propiverine hydrochloride tablets, and paracetamol and pseudoephedrine hydrochloride tablets. The company also offers Xinkaihe warm tea, Ginkgo thirty-seven hawthorn polyphenol capsules, Propolis, McKinley card Calcium Iron zinc and selenium chewable tablets, and Happiness red Luzhou nourishing Okuma. It operates in Beijing, Shanghai and Hong Kong. Kangmei is headquartered in Shenzhen, Guangdong, China.

Kangmei Pharmaceutical Co Ltd (600518) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kangmei Pharma To Acquire Three Hospitals In China For US$82 Million 12
Venture Financing 13
Twist Bioscience Raises Additional USD27 Million in Venture Financing 13
Partnerships 15
Kangmei Pharma Enters into Agreement with BGI Genomics 15
Equity Offering 16
Kangmei Pharma Raises USD1.3 Billion in Private Placement of Shares 16
Kangmei Pharma Plans For Private Placement Of Shares For USD972.4 Million 17
Debt Offering 18
Kangmei Pharma Raises USD154 Million in Public Offering of 7% Notes Due 2021 18
Kangmei Pharma Plans to Raise USD159.21 Million in Public Offering of Bonds 19
Kangmei Pharma Raises USD236.9 Million in Public Offering of 5.38% 2018 First Tranche Notes Due 2018 20
Kangmei Pharma Raises USD454.1 Million in Private Placement of Bonds 21
Kangmei Pharma Raises USD304.7 Million in Public Offering of Third Tranche of 5.47% Notes Due 2022 22
Kangmei Pharma Raises USD300 Million in Public Offering of Second Tranche of 5.29% Notes Due 2022 23
Kangmei Pharma to Raise USD1.6 Billion in Public Offering of Notes 24
Kangmei Pharma Raises USD220.3 Million in Public Offering of Debentures 25
Kangmei Pharma Raises USD369 Million in First Tranche of Public Offering of 3.28% Debentures Due 2017 26
Kangmei Pharma to Raise up to USD391 Million in Private Placement of Bonds 27
Acquisition 28
Kangmei Pharma to Acquire 80% Stake in Huizhou-Based Pharmaceutical Company for USD3.18 million 28
Kangmei Pharma Plans to Acquire Pharmaceutical Company for USD21 Million 29
Kangmei Pharma to Acquire Chongqing Ruitai Pharma for USD12.5 Million 30
Kangmei Pharma to Acquire 80% Stake in Guangdong Xin’ao Pharma for USD9 Million 31
Kangmei Pharma to Acquire Shenzhen Ieman Pharma for USD3.5 Million 32
Kangmei Pharmaceutical Co Ltd – Key Competitors 33
Kangmei Pharmaceutical Co Ltd – Key Employees 34
Kangmei Pharmaceutical Co Ltd – Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kangmei Pharma To Acquire Three Hospitals In China For US$82 Million 12
Twist Bioscience Raises Additional USD27 Million in Venture Financing 13
Kangmei Pharma Enters into Agreement with BGI Genomics 15
Kangmei Pharma Raises USD1.3 Billion in Private Placement of Shares 16
Kangmei Pharma Plans For Private Placement Of Shares For USD972.4 Million 17
Kangmei Pharma Raises USD154 Million in Public Offering of 7% Notes Due 2021 18
Kangmei Pharma Plans to Raise USD159.21 Million in Public Offering of Bonds 19
Kangmei Pharma Raises USD236.9 Million in Public Offering of 5.38% 2018 First Tranche Notes Due 2018 20
Kangmei Pharma Raises USD454.1 Million in Private Placement of Bonds 21
Kangmei Pharma Raises USD304.7 Million in Public Offering of Third Tranche of 5.47% Notes Due 2022 22
Kangmei Pharma Raises USD300 Million in Public Offering of Second Tranche of 5.29% Notes Due 2022 23
Kangmei Pharma to Raise USD1.6 Billion in Public Offering of Notes 24
Kangmei Pharma Raises USD220.3 Million in Public Offering of Debentures 25
Kangmei Pharma Raises USD369 Million in First Tranche of Public Offering of 3.28% Debentures Due 2017 26
Kangmei Pharma to Raise up to USD391 Million in Private Placement of Bonds 27
Kangmei Pharma to Acquire 80% Stake in Huizhou-Based Pharmaceutical Company for USD3.18 million 28
Kangmei Pharma Plans to Acquire Pharmaceutical Company for USD21 Million 29
Kangmei Pharma to Acquire Chongqing Ruitai Pharma for USD12.5 Million 30
Kangmei Pharma to Acquire 80% Stake in Guangdong Xin'ao Pharma for USD9 Million 31
Kangmei Pharma to Acquire Shenzhen Ieman Pharma for USD3.5 Million 32
Kangmei Pharmaceutical Co Ltd, Key Competitors 33
Kangmei Pharmaceutical Co Ltd, Key Employees 34

List of Figures
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsubishi International Food Ingredients, Inc.:戦略・SWOT・企業財務分析
    Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi International Food Ingredients, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Otto Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the ope …
  • Mueller Water Products Inc (MWA):企業の財務・戦略的SWOT分析
    Summary Mueller Water Products Inc (Mueller Water) operates as an industrial equipment company. It manufactures and markets products for transmission, distribution and measurement of water. The company’s products include iron pipe, water metering products, fire hydrants, water and gas valves, and sy …
  • Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-spec …
  • Realm Therapeutics Plc (RLM):製薬・医療:M&Aディール及び事業提携情報
    Summary Realm Therapeutics Plc (Realm Therapeutics), formerly PuriCore Plc is a biopharmaceutical company that develops small molecule therapies for diseases. The company uses its immunomodulatory technology for treating inflammatory diseases in dermatology, ophthalmology, and other diseases. Its pi …
  • Manz AG (M5Z):電力:M&Aディール及び事業提携情報
    Summary Manz AG (Manz) is a manufacturer of high-technology equipment. It produces displays, printed circuit boards and other components for electronic devices. The company provides production equipment for lithium-ion battery cells, super capacitors, battery systems, and capacitors. Manz offers ind …
  • Aequus Pharmaceuticals Inc (AQS):製薬・医療:M&Aディール及び事業提携情報
    Summary Aequus Pharmaceuticals Inc (Aequus Pharmaceuticals) is a drug discovery and development company that develops differentiated drugs. The company’s pipeline products include AQS301, AQS302 and AQS303. Its commercial pipeline comprises ophthalmology products and transplant products. Aequus Phar …
  • Bilcare Ltd (526853):企業の財務・戦略的SWOT分析
    Bilcare Ltd (526853) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nitori Holdings Co Ltd:企業の戦略・SWOT・財務分析
    Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nitori Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Dana Petroleum Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Dana Petroleum Ltd (Dana), a wholly-owned subsidiary of Korea National Oil Corp (KNOC), is an upstream oil and gas company. It explores, develops and produces oil and gas from its assets in the Europe and the Middle East. The company has interests and operations in the UK, the Netherlands, D …
  • Career Education Corporation (CECO):企業の財務・戦略的SWOT分析
    Career Education Corporation (CECO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Yungjin Pharm Co Ltd (003520):製薬・医療:M&Aディール及び事業提携情報
    Summary Yungjin Pharm Co Ltd (Yungjin), a subsidiary of KT&G Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company provides API products such as cephalosporins and other general products. It also off …
  • SurModics Inc (SRDX):医療機器:M&Aディール及び事業提携情報
    Summary SurModics Inc (SurModics) is a provider of device drug delivery coating and in vitro diagnostic technologies. The company offers wide range of advanced technologies that includes medical device coating technologies and surface modification coating technologies. Its technologies are employed …
  • Argonaut Gold Inc.:企業の戦略・SWOT・財務情報
    Argonaut Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Argonaut Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AgaMatrix Inc:医療機器:M&Aディール及び事業提携情報
    Summary AgaMatrix Inc (AgaMatrix) is a medical device company that offers biosensors and blood glucose monitors. The company designs, develops and manufactures diabetes products for pharmaceutical companies. Its products comprise Jazz Wireless 2, blood glucose monitors, Connected Health and AgaMatri …
  • China Investment Corp:企業のM&A・事業提携・投資動向
    China Investment Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Investment Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Sumitomo Dainippon Pharma Co Ltd (4506):企業の財務・戦略的SWOT分析
    Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Penn Virginia Corp (PVAC):石油・ガス:M&Aディール及び事業提携情報
    Summary Penn Virginia Corp (Penn Virginia) is an independent oil and gas company. It explores, develops, and produces crude oil, Natural gas liquids (NGL), and natural gas. The company’s operations consist primarily of drilling unconventional horizontal development wells and operating producing well …
  • Cardia Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures and markets transcatheter septal occluders for cardiac defect patients. The company offers products such as ultrasept ASD occluder, ultrasept LAA occluder, ultrasept PFO occluder, fontan occluder, ultrasept cribriform …
  • Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Astellas Pharma Europe Ltd (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a manufacturer and distributor of drug products. The company provides pharmaceutical drugs in the areas of oncology, transplantation, urology, anti-infective, pain management and dermatology. It also provide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆